Charles Casamento
Executive Director
-
Fordham University, degree in Pharmacy and Iona College, MBA
-
President and CEO of Osteologix, 2004 until 2007, Questcor, 1999 until 2004 and RiboGene, 1993 until 1999
-
Founder in 1999 of Questcor and served as Chairman and CEO through 2004
-
Co-founded in 1989, took public and was CEO of Interneuron (Indevus)
-
Held marketing, sales, finance and business development positions with Sandoz, Hoffmann-LaRoche and Johnson & Johnson
-
Vice President of Business Development and Strategic Planning for the Critical Care Division for and American Hospital Supply Corporation
-
Senior Vice President & General Manager for Pharmaceuticals and Biochemicals at Genzyme from 1985 through 1989
-
Four Biotech company IPOs
Charles (“Chuck”) Casamento – Chuck was President and CEO of Osteologix from October 2004 until April, 2007. Originally a private company founded in Copenhagen, Denmark, during his 29 months at Osteologix, Mr. Casamento commenced operations in the US, completed a financing with Rodman & Renshaw and Roth Capital Partners, took the company public, completed pre-clinical trials on the company's lead product, completed phase I clinical trials and initiated phase II clinical trials. Osteologix was Mr. Casamento's fourth start up company, all of which completed IPOs during his tenure.
​
During his career, Mr. Casamento has held a number of marketing, sales, finance and business development positions with Sandoz, Hoffmann-LaRoche, Johnson & Johnson and American Hospital Supply Corporation where he was Vice President of Business Development and Strategic Planning for the Critical Care Division.
​
He was Senior Vice President & General Manager for Pharmaceuticals and Biochemicals at Genzyme from 1985 through 1989 during which time Genzyme was taken public. In 1989 he co-founded and later took public, Interneuron Pharmaceuticals (Indevus) which eventually reached a $1.6 billion valuation. In 1993 Mr. Casamento joined RiboGene as Chairman, President and CEO. He took the Company public and completed several major corporate collaborations including a merger with another public corporation to form Questcor Pharmaceuticals, where he held roles as Chairman, CEO and President. In 2014 Questcor was acquired by Mallinckrodt for approximately $6 Billion.
​
He is a Director and Board member at Relmada Therapeutics, Eton Pharmaceuticals, AzurRx Biotherapeutics and International Stem Cell Corporation and is Chairman of the Board of Relmada Therapeutics. He was originally licensed to practice Pharmacy in New York and New Jersey. During his career he has served as a Director on the Boards of twelve biotech/pharma companies and two not for profit organizations including Vice Chairman of The Catholic Medical Missions Board a large not for profit health care organization.
A graduate of Fordham University in New York City and Iona College in New Rochelle, New York, Mr. Casamento has a degree in Pharmacy and an MBA.